Does Humana Cover Fosamax (Alendronate)? Formulary, Prior Auth, and Appeal Guide

What Fosamax (Alendronate) Is and Why Coverage Matters

Alendronate is a first-line bisphosphonate approved by the FDA for treating and preventing osteoporosis in postmenopausal women, men with osteoporosis, and patients on long-term glucocorticoid therapy. [1] The brand-name product, Fosamax, launched in 1995, but generic alendronate has been available since 2008 and now accounts for the vast majority of prescriptions written. The distinction between brand and generic determines almost everything about how Humana handles the claim.

Osteoporosis affects an estimated 10 million Americans age 50 and older, with another 44 million classified as having low bone density, according to the National Osteoporosis Foundation figures cited in the Surgeon General's 2004 bone health report. [2] Fracture prevention is the core clinical goal. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027 women with a prior vertebral fracture), showed alendronate 10 mg daily reduced clinical fracture risk by 55% and hip fracture risk by 51% over 36 months compared with placebo (P<0.001). [3] A second FIT cohort of 4,432 women without a prior vertebral fracture showed a 36% reduction in clinical fractures over 48 months in participants with femoral neck T-scores at or below minus 2.5. [4]

These trial results underpin why the American College of Rheumatology, the Endocrine Society, and the American Association of Clinical Endocrinology all list alendronate as a first-line pharmacological option. [5] When Humana's utilization management team reviews an alendronate claim, they are working from clinical evidence this strong. That generally works in the patient's favor.

How Humana's Formulary System Works for Alendronate

Humana assigns every covered drug a formulary tier that controls your out-of-pocket cost. Generic alendronate (sodium tablets, 5 mg, 10 mg, 35 mg, 40 mg, 70 mg) lands on Tier 1 or Tier 2 across the majority of Humana commercial plans and Medicare Advantage (MA) Part D plans. Tier 1 typically carries a $0 to $5 copay at preferred pharmacies; Tier 2 runs $10 to $25 for a 30-day supply.

Brand-name Fosamax is a different situation. Most Humana formularies place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which means copays of $45 to $100 per fill or coinsurance of 30 to 50 percent. Some Humana MA plans exclude brand Fosamax entirely and require use of the generic equivalent. This is standard practice under CMS Part D formulary rules, which permit plan sponsors to require generic substitution when a therapeutically equivalent generic is available. [6]

The specific tier for your plan is visible in the "Drug Pricing and Formulary" tool on Humana.com after you enter your plan ID. Formularies update January 1 each year, and Humana may issue mid-year updates for newly generic drugs. Confirming tier status before filling any 90-day supply avoids billing surprises.

HealthRX Formulary Check Framework for Alendronate on Humana:

1. Go to Humana.com, select "Find a Drug," and search "alendronate sodium."
2. Confirm the salt form and strength match your prescription (70 mg weekly tablet is the most common maintenance dose).
3. Compare the preferred pharmacy cost versus the mail-order cost. Humana Mail Order (Humana Pharmacy) frequently reduces the Tier 1 generic copay to $0 for a 90-day supply on qualifying MA plans.
4. If only brand Fosamax appears, ask the pharmacist to contact Humana and confirm whether a formulary exception for brand-name coverage is needed or whether generic substitution applies automatically.
5. Print or screenshot the formulary lookup result with the date. You will need this if filing an appeal.

Prior Authorization for Fosamax on Humana

Prior authorization (PA) is rarely required for generic alendronate on Humana. The drug's long safety record, generic availability, and inclusion in national osteoporosis guidelines mean most Humana plans treat it as a straightforward fill. [7]

Brand-name Fosamax is more complicated. Some Humana commercial and MA plans do require a PA before covering brand Fosamax, with typical criteria including a documented diagnosis of osteoporosis or documented bone mineral density (BMD) T-score at or below minus 2.5 at the spine or hip, or a T-score between minus 1.0 and minus 2.5 with one or more additional fracture risk factors per FRAX tool calculations, plus a prescriber attestation that the patient cannot use the generic formulation (for example, a documented intolerance to tablet excipients). [8]

The American Association of Clinical Endocrinology 2020 guidelines state that "pharmacological therapy is recommended for postmenopausal women with osteoporosis (T-score at or below -2.5 at the spine, femoral neck, or total hip) or low bone mass and a 10-year probability of major osteoporotic fracture at or above 20% by FRAX." [9] Humana PA reviewers routinely cite this threshold, so a PA request should include DXA scan results, FRAX score, and fracture history if any.

Typical PA processing time for Humana is 72 hours for standard review and 24 hours for urgent review when a prescriber certifies clinical urgency. If the PA is approved, it typically covers 12 months before requiring renewal.

Step Therapy Requirements

Step therapy on Humana for brand Fosamax generally means the patient must have tried and failed, or have a documented contraindication to, generic alendronate first. The required trial period varies by plan but is commonly defined as at least 30 consecutive days on the generic formulation. [10]

Documented failure criteria accepted by most Humana plans include: an adverse gastrointestinal event requiring discontinuation (esophageal irritation, severe dyspepsia), persistent upper GI symptoms despite correct dosing technique (taking with 6 to 8 ounces of plain water, remaining upright for 30 minutes), or a laboratory-confirmed drug interaction. Atypical femur fracture or osteonecrosis of the jaw during prior bisphosphonate therapy is an absolute contraindication to continuing any bisphosphonate and bypasses step therapy entirely. [11]

Generic alendronate and brand Fosamax contain the same active moiety, so true pharmacological failure of one predicts failure of the other. The practical purpose of step therapy here is cost containment, not clinical optimization. If a prescriber believes brand-name is clinically necessary due to inactive ingredient intolerances, that clinical rationale must be documented in the PA request to clear the step requirement.

What Happens When Humana Denies Fosamax Coverage

A denial letter from Humana will specify one of several reasons: not on formulary, step therapy not met, PA required, or medical necessity not established. Each reason has a specific appeal pathway, and the timelines differ between commercial plans and Medicare Advantage.

Commercial Humana Plans

The internal appeal must be filed within 180 days of the denial. Humana must respond within 30 days for standard appeals or 72 hours for expedited appeals. If the internal appeal is denied, the member may pursue an external independent review within four months, per the ACA's external review requirements. [12]

Humana Medicare Advantage (Part D)

The Medicare appeals process follows CMS-mandated steps. First, request a Coverage Determination in writing. If denied, file a redetermination request with Humana within 60 days. Humana has 7 days (standard) or 72 hours (expedited) to respond. If Humana upholds the denial, the next level is a Reconsideration by the independent review entity MAXIMUS Federal Services, which CMS contracts for Part D appeals. MAXIMUS has a 7-day standard or 72-hour expedited review window. [13] If MAXIMUS sides with Humana, the member may escalate to an Administrative Law Judge hearing (if the amount in controversy exceeds $180 in 2025), then the Medicare Appeals Council, and finally federal district court.

Approval rates at the MAXIMUS level for bisphosphonate appeals are not publicly reported by drug name, but CMS data show that Part D enrollees who pursue independent review at MAXIMUS win reversal in approximately 23% of cases annually. [14]

Building a Strong Appeal

Include the following documents in every Fosamax appeal filed with Humana:

• DXA scan report (spine and hip T-scores, scan date, facility name)
• FRAX calculation printout with 10-year fracture probability
• Clinical notes documenting fracture history or high-risk conditions (glucocorticoid use, rheumatoid arthritis, prior fragility fracture)
• Letter of medical necessity from the prescribing physician specifying why brand Fosamax is required if generic is available
• Copies of any failed generic trial documentation (pharmacy records, adverse event notes)
• The formulary printout or formulary exception request if filing a non-formulary appeal

The Endocrine Society's 2019 clinical practice guideline states: "Bisphosphonates are recommended as first-line therapy for most postmenopausal women with osteoporosis because of their antifracture efficacy, long-term safety data, and low cost." [15] Quoting this guideline directly in the appeal letter anchors the medical necessity argument in peer-reviewed clinical consensus.

Clinical Evidence Supporting Alendronate Coverage Approval

Humana's medical policy on bisphosphonates draws from the same evidence base that informs prescribing guidelines. The FIT trial remains the most cited key study. In the vertebral fracture arm (N=2,027), alendronate reduced the risk of new vertebral fractures by 47% over 3 years (relative risk 0.53 to 95% CI 0.41 to 0.68). [3] In the clinical fracture arm (N=4,432), the 36-month number needed to treat to prevent one hip fracture was 91 in high-risk participants. [4]

The FLEX trial (Fracture Intervention Trial Long-Term Extension), published in JAMA in 2006 (N=1,099), evaluated outcomes after 5 years of alendronate followed by continued therapy versus discontinuation. Women who continued for 10 total years maintained higher BMD and lower risk of clinical vertebral fracture compared with those who stopped at 5 years (relative risk 0.55 for clinical vertebral fractures, P<0.05). [16] This evidence supports Humana coverage for long-term prescriptions beyond an initial 12-month authorization period.

The HORIZON Key Fracture Trial (N=7,765, published in NEJM 2007) tested zoledronic acid (a related bisphosphonate given IV annually) and showed a 70% reduction in vertebral fractures over 3 years. [17] Humana reviewers familiar with this class effect will recognize that alendronate's evidence base is at least as strong for oral administration, reinforcing coverage decisions for the oral bisphosphonate category as a whole.

For patients who cannot tolerate oral alendronate due to esophageal disease, risedronate, ibandronate, and zoledronic acid are formulary alternatives on most Humana plans, but each requires its own PA review under specific clinical criteria.

Cost of Alendronate With and Without Humana Coverage

Generic alendronate 70 mg weekly tablets carry a retail cash price of approximately $4 to $15 per month at GoodRx contracted pharmacies, which is among the lowest of any osteoporosis treatment. [18] Brand Fosamax lists at roughly $80 per month. This cost gap is the primary driver of Humana's step therapy and generic-first policies.

When Humana covers generic alendronate at Tier 1, the member typically pays $0 to $5 per fill. A 90-day supply through Humana Pharmacy mail order may cost $0 under certain MA-PD plan designs. Out-of-pocket costs reset with each plan year, so patients approaching the Medicare Part D coverage gap (the "donut hole," which begins at $2 to 000 in total drug costs in 2025 under the Inflation Reduction Act restructuring) should account for timing of refills. [19]

Manufacturer Savings Cards

The Fosamax manufacturer savings card is not usable with federal insurance programs. CMS regulations prohibit applying manufacturer copay cards toward the Medicare Part D out-of-pocket threshold, meaning the card does not count toward the $2,000 cap. [20] Humana commercial plan members may use manufacturer assistance programs, but individual plan contracts vary. The savings card is most relevant for commercially insured patients who are prescribed brand Fosamax and cannot get the PA approved.

Patients without any insurance, or those whose Humana plan excludes alendronate, should check GoodRx, Mark Cuban's Cost Plus Drugs (which lists alendronate 70 mg at $3.40 for 4 tablets), and community health center 340B pricing. [21]

Who Qualifies for Alendronate Under Humana Coverage Criteria

Humana's medical necessity criteria for alendronate align closely with the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) thresholds. Coverage is approved for:

• Postmenopausal women with a DXA T-score at or below minus 2.5 at the lumbar spine, femoral neck, or total hip
• Postmenopausal women with T-score between minus 1.0 and minus 2.5 and a FRAX 10-year major osteoporotic fracture probability at or above 20% or hip fracture probability at or above 3%
• Men age 50 and older with osteoporosis by DXA criteria
• Men and women initiating or continuing glucocorticoid therapy at a dose of prednisone 7.5 mg per day or more for 3 months or longer, per the 2017 ACR glucocorticoid-induced osteoporosis guideline [22]
• Patients with a prior low-trauma fragility fracture of the hip or spine regardless of DXA T-score

Fosamax is not approved by the FDA for weight loss, and Humana will not cover it for that indication. [1] This is a firm policy with no appeal pathway because coverage of off-label weight-loss uses is excluded by contract language, not just formulary design.

How Humana Handles Alendronate for Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is the most common cause of secondary osteoporosis in the United States, affecting patients on prednisone, methylprednisolone, dexamethasone, or equivalent agents for conditions such as rheumatoid arthritis, inflammatory bowel disease, and asthma. [22]

Humana's PA criteria for GIOP typically require documentation of the glucocorticoid prescription (drug name, dose, and expected duration), a baseline DXA scan or FRAX score, and a diagnosis code reflecting the underlying inflammatory condition. The 2017 ACR guideline on GIOP recommends initiating bisphosphonate therapy in patients receiving prednisone 7.5 mg per day or more for 3 or more months who have a FRAX 10-year major osteoporotic fracture probability at or above 10% (using a calculator that adjusts for glucocorticoid dose). [22]

Citing this threshold explicitly in the PA submission accelerates approval. The ACR guideline also provides medium-dose and high-dose glucocorticoid sub-criteria that apply to younger patients, which may be relevant for Humana commercial plan members under age 50 who would not meet standard postmenopausal osteoporosis thresholds. [22]

Switching From Brand Fosamax to Generic Alendronate

The FDA classifies generic alendronate sodium as AB-rated (therapeutically equivalent) to brand Fosamax. [23] This rating means the generic has demonstrated bioequivalence within the FDA's standard 80 to 125 percent confidence interval for both Cmax and AUC. Pharmacists may substitute the generic automatically in all 50 states unless the prescriber writes "dispense as written."

Patients switching from brand to generic should take the same dose and same administration instructions (once weekly, first thing in the morning, with 6 to 8 ounces of plain water, 30 minutes before any food or other medication). [1] No dose adjustment is needed. Bone mineral density monitoring with DXA is generally recommended every 1 to 2 years during active treatment, per the BHOF guidelines. [24]

Some patients notice differences in tablet size or coating between manufacturers when switching between generic suppliers. This does not affect bioequivalence. If GI symptoms worsen after a generic switch, the prescriber should assess whether the issue is consistent with a known alendronate class effect (upper GI irritation) versus an excipient sensitivity, which is rare but documentable for PA purposes.

Humana Medicare Advantage vs. Commercial Coverage: Key Differences

Humana Medicare Advantage Part D formularies follow CMS model formulary requirements, which require inclusion of drugs in all six protected classes (though osteoporosis drugs are not in a protected class). This means bisphosphonates can be tiered or restricted. [6]

The CMS Annual Notice of Change (ANOC) that Humana sends each September documents any formulary changes taking effect January 1. If alendronate moves from Tier 1 to Tier 2, or if new step therapy criteria are added, the ANOC is the legal notification. Members have until December 31 to switch plans during the Annual Enrollment Period (AEP). [13]

Humana commercial group plans follow ERISA and state insurance regulations. These plans have more variation in formulary structure than MA plans. Self-funded employer plans (which Humana administers but does not bear insurance risk for) may have fully custom formularies with no state mandate for bisphosphonate coverage.

Confirming which type of Humana plan you have (fully insured commercial, self-funded commercial, or Medicare Advantage) determines which appeals process and which regulatory protections apply.